vs
Side-by-side financial comparison of GYRE THERAPEUTICS, INC. (GYRE) and LINKBANCORP, Inc. (LNKB). Click either name above to swap in a different company.
LINKBANCORP, Inc. is the larger business by last-quarter revenue ($46.0M vs $37.2M, roughly 1.2× GYRE THERAPEUTICS, INC.). LINKBANCORP, Inc. runs the higher net margin — 6.4% vs -3.7%, a 10.1% gap on every dollar of revenue. On growth, GYRE THERAPEUTICS, INC. posted the faster year-over-year revenue change (33.4% vs 7.3%). LINKBANCORP, Inc. produced more free cash flow last quarter ($23.8M vs $-5.8M). Over the past eight quarters, GYRE THERAPEUTICS, INC.'s revenue compounded faster (17.0% CAGR vs 6.6%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
LINKBANCORP, Inc. is a US-based bank holding company that offers comprehensive retail and commercial banking services to individual consumers, small businesses, and mid-sized enterprises. Its core offerings include deposit accounts, lending products, wealth management solutions, and digital banking services, primarily serving customers across regional markets in Pennsylvania.
GYRE vs LNKB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $37.2M | $46.0M |
| Net Profit | $-1.4M | $2.9M |
| Gross Margin | 95.3% | — |
| Operating Margin | 0.3% | 8.5% |
| Net Margin | -3.7% | 6.4% |
| Revenue YoY | 33.4% | 7.3% |
| Net Profit YoY | -340.1% | -61.2% |
| EPS (diluted) | $-0.01 | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $37.2M | $46.0M | ||
| Q3 25 | $30.6M | $44.8M | ||
| Q2 25 | $26.8M | $42.3M | ||
| Q1 25 | $22.1M | $53.4M | ||
| Q4 24 | $27.9M | $42.9M | ||
| Q3 24 | $25.5M | $42.9M | ||
| Q2 24 | $25.2M | $41.3M | ||
| Q1 24 | $27.2M | $40.5M |
| Q4 25 | $-1.4M | $2.9M | ||
| Q3 25 | $5.9M | $7.8M | ||
| Q2 25 | $1.6M | $7.4M | ||
| Q1 25 | $3.7M | $15.3M | ||
| Q4 24 | $569.0K | $7.6M | ||
| Q3 24 | $2.9M | $7.1M | ||
| Q2 24 | $4.5M | $5.8M | ||
| Q1 24 | $9.9M | $5.7M |
| Q4 25 | 95.3% | — | ||
| Q3 25 | 94.7% | — | ||
| Q2 25 | 95.7% | — | ||
| Q1 25 | 95.9% | — | ||
| Q4 24 | 95.8% | — | ||
| Q3 24 | 96.2% | — | ||
| Q2 24 | 96.9% | — | ||
| Q1 24 | 96.4% | — |
| Q4 25 | 0.3% | 8.5% | ||
| Q3 25 | 22.7% | 22.3% | ||
| Q2 25 | 8.1% | 22.4% | ||
| Q1 25 | 10.3% | 36.0% | ||
| Q4 24 | 2.4% | 22.6% | ||
| Q3 24 | 16.6% | 21.3% | ||
| Q2 24 | 12.7% | 18.0% | ||
| Q1 24 | 29.7% | 18.1% |
| Q4 25 | -3.7% | 6.4% | ||
| Q3 25 | 19.4% | 17.5% | ||
| Q2 25 | 5.9% | 17.5% | ||
| Q1 25 | 16.9% | 28.7% | ||
| Q4 24 | 2.0% | 17.7% | ||
| Q3 24 | 11.2% | 16.5% | ||
| Q2 24 | 18.0% | 14.1% | ||
| Q1 24 | 36.6% | 14.1% |
| Q4 25 | $-0.01 | $0.08 | ||
| Q3 25 | $0.03 | $0.21 | ||
| Q2 25 | $0.00 | $0.20 | ||
| Q1 25 | $0.00 | $0.41 | ||
| Q4 24 | $0.00 | $0.21 | ||
| Q3 24 | $0.01 | $0.19 | ||
| Q2 24 | $0.01 | $0.16 | ||
| Q1 24 | $0.03 | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $52.4M | $52.3M |
| Total DebtLower is stronger | — | $177.3M |
| Stockholders' EquityBook value | $106.0M | $306.4M |
| Total Assets | $166.1M | $3.1B |
| Debt / EquityLower = less leverage | — | 0.58× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $52.4M | $52.3M | ||
| Q3 25 | $60.0M | $194.2M | ||
| Q2 25 | $54.4M | $155.1M | ||
| Q1 25 | $29.9M | $220.2M | ||
| Q4 24 | $26.7M | $166.1M | ||
| Q3 24 | $25.1M | $191.2M | ||
| Q2 24 | $25.1M | $181.7M | ||
| Q1 24 | $37.4M | $172.3M |
| Q4 25 | — | $177.3M | ||
| Q3 25 | — | $102.3M | ||
| Q2 25 | — | $102.3M | ||
| Q1 25 | — | $102.7M | ||
| Q4 24 | — | $112.5M | ||
| Q3 24 | — | $102.4M | ||
| Q2 24 | — | $102.3M | ||
| Q1 24 | — | $102.2M |
| Q4 25 | $106.0M | $306.4M | ||
| Q3 25 | $101.9M | $305.5M | ||
| Q2 25 | $92.0M | $298.0M | ||
| Q1 25 | $68.1M | $294.1M | ||
| Q4 24 | $63.3M | $280.2M | ||
| Q3 24 | $63.2M | $277.4M | ||
| Q2 24 | $60.4M | $271.4M | ||
| Q1 24 | $56.6M | $268.2M |
| Q4 25 | $166.1M | $3.1B | ||
| Q3 25 | $159.4M | $3.1B | ||
| Q2 25 | $152.6M | $2.9B | ||
| Q1 25 | $129.8M | $2.9B | ||
| Q4 24 | $125.4M | $2.9B | ||
| Q3 24 | $125.2M | $2.9B | ||
| Q2 24 | $120.9M | $2.9B | ||
| Q1 24 | $122.0M | $2.8B |
| Q4 25 | — | 0.58× | ||
| Q3 25 | — | 0.33× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.35× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.37× | ||
| Q2 24 | — | 0.38× | ||
| Q1 24 | — | 0.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.6M | $25.3M |
| Free Cash FlowOCF − Capex | $-5.8M | $23.8M |
| FCF MarginFCF / Revenue | -15.5% | 51.7% |
| Capex IntensityCapex / Revenue | 0.4% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 8.59× |
| TTM Free Cash FlowTrailing 4 quarters | $-180.0K | $55.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.6M | $25.3M | ||
| Q3 25 | $4.7M | $23.6M | ||
| Q2 25 | $2.1M | $6.3M | ||
| Q1 25 | $-129.0K | $2.6M | ||
| Q4 24 | $-2.8M | $25.4M | ||
| Q3 24 | $1.7M | $14.0M | ||
| Q2 24 | $-5.5M | $6.4M | ||
| Q1 24 | $2.9M | $-771.0K |
| Q4 25 | $-5.8M | $23.8M | ||
| Q3 25 | $4.0M | $23.2M | ||
| Q2 25 | $1.8M | $6.1M | ||
| Q1 25 | $-251.0K | $2.2M | ||
| Q4 24 | $-2.8M | $22.6M | ||
| Q3 24 | $1.0M | $13.1M | ||
| Q2 24 | $-6.9M | $6.3M | ||
| Q1 24 | $2.7M | $-1.2M |
| Q4 25 | -15.5% | 51.7% | ||
| Q3 25 | 13.1% | 51.8% | ||
| Q2 25 | 6.8% | 14.5% | ||
| Q1 25 | -1.1% | 4.2% | ||
| Q4 24 | -10.1% | 52.6% | ||
| Q3 24 | 4.1% | 30.5% | ||
| Q2 24 | -27.5% | 15.3% | ||
| Q1 24 | 9.8% | -3.0% |
| Q4 25 | 0.4% | 3.2% | ||
| Q3 25 | 2.2% | 0.8% | ||
| Q2 25 | 1.0% | 0.4% | ||
| Q1 25 | 0.6% | 0.7% | ||
| Q4 24 | 0.2% | 6.7% | ||
| Q3 24 | 2.7% | 2.1% | ||
| Q2 24 | 5.8% | 0.1% | ||
| Q1 24 | 0.9% | 1.1% |
| Q4 25 | — | 8.59× | ||
| Q3 25 | 0.79× | 3.01× | ||
| Q2 25 | 1.32× | 0.85× | ||
| Q1 25 | -0.03× | 0.17× | ||
| Q4 24 | -4.85× | 3.35× | ||
| Q3 24 | 0.60× | 1.97× | ||
| Q2 24 | -1.21× | 1.10× | ||
| Q1 24 | 0.29× | -0.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
